Anavex sets 2026 annual shareholder meeting date

Anavex Life Sciences Corp. scheduled its 2026 Annual Meeting of Stockholders for September 24, 2026.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Anavex Life Sciences Corp. scheduled its 2026 Annual Meeting of Stockholders for September 24, 2026. The Board of Directors set July 31, 2026 as the record date, determining which stockholders are entitled to receive notice of and vote at the meeting.

The company also set revised timing guidelines for stockholder proposals and director nominations because the 2026 meeting will occur more than 30 days after the prior year’s meeting. Proposals and nominations received on or before July 10, 2026 will be considered submitted within a reasonable time before proxy materials are printed and mailed.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

2026 Annual Meeting date: September 24, 2026 Record date: July 31, 2026 Proposal timing guideline: July 10, 2026 +1 more

4 metrics

2026 Annual Meeting date September 24, 2026 Date set by Board of Directors

Record date July 31, 2026 Determines stockholders entitled to vote

Proposal timing guideline July 10, 2026 Considered a reasonable time before proxy printing

Company address 630 5th Avenue, 20th Floor, New York, NY 10111 Principal executive offices for proposal submissions

Key Terms

Annual Meeting of Stockholders, record date, Rule 14a-8, Rule 14a-5(f), +1 more

5 terms

Annual Meeting of Stockholders financial

"the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”)"

record date financial

"July 31, 2026, as the record date for the determination of stockholders"

The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.

Rule 14a-8 regulatory

"submitted for inclusion in the Company’s proxy materials pursuant to Rule 14a-8 under the Exchange Act"

Rule 14a-8 is a U.S. Securities and Exchange Commission regulation that lets eligible shareholders put proposals on a public company’s proxy ballot for an annual meeting, provided they meet basic ownership and filing requirements. It matters to investors because it creates a formal way to raise governance or strategic issues and force a company-wide vote—like getting an item onto the agenda of a neighborhood association meeting once you’ve lived there long enough—so shareholders can push for change or influence management decisions.

Rule 14a-5(f) regulatory

"in accordance with Rule 14a-5(f) under the Securities Exchange Act of 1934"

proxy materials financial

"before the Company begins to print and send its proxy materials"

Proxy materials are the packet of documents sent to shareholders that explain items to be voted on at a company meeting and include the actual ballot or instructions for casting a vote. Think of them as a voting packet that lays out who’s running the company, major proposals (like pay, mergers, or board changes), and arguments for and against each item. Investors care because those votes shape corporate direction, affect risk and future profits, and can influence share value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Anavex Life Sciences (AVXL) holding its 2026 Annual Meeting?

Anavex Life Sciences plans to hold its 2026 Annual Meeting of Stockholders on September 24, 2026. The definitive proxy statement will later provide the exact time, location, and additional details about the agenda and voting procedures for AVXL stockholders.

What is the record date for Anavex Life Sciences (AVXL) 2026 Annual Meeting?

The record date for Anavex Life Sciences’ 2026 Annual Meeting is July 31, 2026. Stockholders of record at the close of business on that date will be entitled to receive notice of the meeting and vote on the matters presented.

What is the deadline for stockholder proposals for AVXL’s 2026 Annual Meeting?

Anavex Life Sciences will treat stockholder proposals received on or before July 10, 2026 as received within a reasonable time before proxy materials are printed. This timing applies to proposals submitted under Rule 14a-8 and those submitted outside that rule.

How can AVXL stockholders submit director nominations for the 2026 Annual Meeting?

Stockholders may submit director nominations to Anavex Life Sciences’ principal executive offices at 630 5th Avenue, 20th Floor, New York, NY 10111. Nominations received on or before July 10, 2026 will be considered timely for inclusion in the company’s proxy process.

Why did Anavex Life Sciences update proposal deadlines for the 2026 Annual Meeting?

The 2026 Annual Meeting will occur more than 30 days after the anniversary of the 2025 meeting. Because of this timing difference, Anavex Life Sciences provided updated proposal and nomination deadlines consistent with Rule 14a-5(f) under the Exchange Act.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/26/2026 - 06:15 AM EDT

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 25, 2026

ANAVEX LIFE SCIENCES CORP.

(Exact name of Registrant as Specified in Its Charter)

Nevada	001-37606	98-0608404
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

630 5th Avenue, 20th Floor New York, NY USA		10111
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 1-844-689-3939

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		AVXL		Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On June 25, 2026, the Board of Directors (the “Board”) of Anavex Life Sciences Corp. (the “Company”) established September 24, 2026, as the date of the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) and July 31, 2026, as the record date for the determination of stockholders entitled to notice of and to vote at the 2026 Annual Meeting. The time, location and additional details for the 2026 Annual Meeting will be set forth in the Company’s definitive proxy statement for the 2026 Annual Meeting.

As the date of the 2026 Annual Meeting will be more than 30 days after the anniversary of the Company’s 2025 Annual Meeting of Stockholders, the Company is providing notice of the revised deadlines for submission of any qualified stockholder proposal or qualified stockholder nomination in accordance with Rule 14a-5(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

For the 2026 Annual Meeting, (a) any stockholder proposal submitted for inclusion in the Company’s proxy materials pursuant to Rule 14a-8 under the Exchange Act (“Rule 14a-8”) and (b) any stockholder proposal or director nomination submitted outside of Rule 14a-8, must be received by the Company at its principal executive offices at the following address, Anavex Life Sciences Corp., 630 5th Avenue, 20th Floor, New York, NY 10111, a reasonable time before the Company begins to print and send its proxy materials. The Company will consider proposals and director nominations received on or before July 10, 2026, to be received within a reasonable time before the Company begins to print and send its proxy materials.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ANAVEX LIFE SCIENCES CORP.

Date: June 26, 2026	By:	/s/ Sandra Boenisch
		Sandra Boenisch, CPA, CGA Principal Financial Officer, Treasurer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents